166 related articles for article (PubMed ID: 18618506)
21. Targeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.
Hu H; Qiu Y; Guo M; Huang Y; Fang L; Peng Z; Ji W; Xu Y; Shen S; Yan Y; Huang X; Zheng J; Su C
Oncotarget; 2015 Jan; 6(2):1079-89. PubMed ID: 25473902
[TBL] [Abstract][Full Text] [Related]
22. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
[TBL] [Abstract][Full Text] [Related]
23. Enhanced sensitivity of hepatocellular carcinoma cells to chemotherapy with a Smac-armed oncolytic adenovirus.
Pan QW; Zhong SY; Liu BS; Liu J; Cai R; Wang YG; Liu XY; Qian C
Acta Pharmacol Sin; 2007 Dec; 28(12):1996-2004. PubMed ID: 18031615
[TBL] [Abstract][Full Text] [Related]
24. ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis.
Yun CO; Kim E; Koo T; Kim H; Lee YS; Kim JH
Cancer Gene Ther; 2005 Jan; 12(1):61-71. PubMed ID: 15375379
[TBL] [Abstract][Full Text] [Related]
25. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL.
Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K
Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578
[TBL] [Abstract][Full Text] [Related]
26. An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma.
Li X; Su Y; Sun B; Ji W; Peng Z; Xu Y; Wu M; Su C
Mol Cancer Ther; 2016 Jul; 15(7):1436-51. PubMed ID: 27196772
[TBL] [Abstract][Full Text] [Related]
27. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X
Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468
[TBL] [Abstract][Full Text] [Related]
28. Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer.
Zhang Y; Qin X; Zhang Y; Zhao L; Wang Y; Liu X; Yao L
J Cancer Res Clin Oncol; 2008 Feb; 134(2):219-26. PubMed ID: 17632733
[TBL] [Abstract][Full Text] [Related]
29. An oncolytic adenovirus that expresses the HAb18 and interleukin 24 genes exhibits enhanced antitumor activity in hepatocellular carcinoma cells.
Yuan S; Fang X; Xu Y; Ni A; Liu XY; Chu L
Oncotarget; 2016 Sep; 7(37):60491-60502. PubMed ID: 27528029
[TBL] [Abstract][Full Text] [Related]
30. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice.
Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X
Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766
[TBL] [Abstract][Full Text] [Related]
31. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
Zhong S; Yu D; Wang Y; Qiu S; Wu S; Liu XY
Acta Oncol; 2010; 49(1):91-9. PubMed ID: 19734998
[TBL] [Abstract][Full Text] [Related]
32. Potent anti-tumour activity of a novel conditionally replicating adenovirus for melanoma via inhibition of migration and invasion.
Jiang G; Yang CS; Xu D; Sun C; Zheng JN; Lei TC; Liu YQ
Br J Cancer; 2014 May; 110(10):2496-505. PubMed ID: 24714752
[TBL] [Abstract][Full Text] [Related]
33. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
34. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
He XP; Su CQ; Wang XH; Pan X; Tu ZX; Gong YF; Gao J; Liao Z; Jin J; Wu HY; Man XH; Li ZS
Cancer Lett; 2009 Nov; 285(1):89-98. PubMed ID: 19481338
[TBL] [Abstract][Full Text] [Related]
35. Synergistic Anti-tumour Effects of Quercetin and Oncolytic Adenovirus expressing TRAIL in Human Hepatocellular Carcinoma.
Zou H; Zheng YF; Ge W; Wang SB; Mou XZ
Sci Rep; 2018 Feb; 8(1):2182. PubMed ID: 29391509
[TBL] [Abstract][Full Text] [Related]
36. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer.
Wirth T; Zender L; Schulte B; Mundt B; Plentz R; Rudolph KL; Manns M; Kubicka S; Kühnel F
Cancer Res; 2003 Jun; 63(12):3181-8. PubMed ID: 12810646
[TBL] [Abstract][Full Text] [Related]
37. Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL-IETD-Smac gene with broad antitumor effect.
Wang SB; Tan Y; Lei W; Wang YG; Zhou XM; Jia XY; Zhang KJ; Chu L; Liu XY; Qian WB
Hum Gene Ther; 2012 Sep; 23(9):992-1002. PubMed ID: 22530834
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.
Li Y; Zhang B; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Li L; Zheng J
J Cancer Res Clin Oncol; 2013 Jun; 139(6):933-41. PubMed ID: 23443256
[TBL] [Abstract][Full Text] [Related]
39. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy.
Cai Y; Liu X; Huang W; Zhang K; Liu XY
Acta Biochim Biophys Sin (Shanghai); 2012 Jun; 44(6):535-43. PubMed ID: 22635106
[TBL] [Abstract][Full Text] [Related]
40. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
